Lipocine to Present at the Ladenburg Thalmann 2017 Healthcare Conference
September 19 2017 - 2:02PM
Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company,
announced today that Dr. Mahesh Patel, Chairman, President and CEO,
will provide a corporate overview at the Ladenburg Thalmann 2017
Healthcare Conference, being held September 26, 2017 at the Sofitel
Hotel, in New York City.
Presentation DetailsDate:
Tuesday, September 26th Time:
10:30 am Eastern TimeLocation: OrleansWebcast:
http://wsw.com/webcast/ladenburg3/lpcn
About Lipocine
Lipocine Inc. is a specialty pharmaceutical company developing
innovative pharmaceutical products for use in men's and women's
health using its proprietary drug delivery technologies. Lipocine’s
clinical development pipeline includes three development programs
TLANDO, LPCN 1111 and LPCN 1107. TLANDO, a novel oral prodrug
of testosterone containing testosterone undecanoate, is designed to
help restore normal testosterone levels in hypogonadal men. TLANDO
was well tolerated and met the primary efficacy end-points in Phase
3 testing with twice daily dosing and is currently under FDA
review. LPCN 1111, a novel oral prodrug of testosterone,
originated and is being developed by Lipocine as a next-generation
oral testosterone product with potential for once-daily dosing and
is currently in Phase 2 testing. LPCN 1107 is potentially the
first oral hydroxyprogesterone caproate product candidate indicated
for the prevention of recurrent preterm birth and has been granted
orphan drug designation by the FDA. An End of Phase 2 meeting with
the FDA has been completed. For more information, please visit
www.lipocine.com.
CONTACT: Morgan BrownExecutive Vice President
& Chief Financial OfficerPhone: (801) 994-7383
mb@lipocine.com
Investors:Hans Vitzhum Phone: (646)
597-6979hans@lifesciadviors.com
Lipocine (NASDAQ:LPCN)
Historical Stock Chart
From Apr 2024 to May 2024
Lipocine (NASDAQ:LPCN)
Historical Stock Chart
From May 2023 to May 2024